Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107628 | 0.89 | PIK3CD (0.35) | PIK3CDACHEBCHE | |
| SCHEMBL23945693 | 0.88 | ACHE (0.32) | PIK3CDACHEBCHE | |
| SCHEMBL24673305 | 0.84 | — | — | |
| SCHEMBL22837640 | 0.83 | HRH3 (0.36) | PIK3CDACHEBCHE | |
| SCHEMBL23559993 | 0.80 | NCF1 (0.41) | PIK3CDACHE | |
| SCHEMBL25108777 | 0.80 | GNAO1 (0.37) | PIK3CDACHEBCHE | |
| SCHEMBL24673628 | 0.79 | ACHE (0.34) | PIK3CDACHEBCHE | |
| SCHEMBL16549320 | 0.78 | PIK3CD (0.45) | PIK3CD | |
| SCHEMBL22856068 | 0.78 | HRH3 (0.39) | PIK3CDACHEBCHE | |
| SCHEMBL22790851 | 0.76 | ACHE (0.37) | PIK3CDACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885ACHE 2778/4885BCHE 2634/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | PIK3CD 2371/4885ACHE 3617/4885BCHE 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.